HOME> product

Acipimox sodium

Sales marketing
Bioactivity Acipimox (K-9321) sodium, a nicotinic acid analogue, is an antilipolytic compound. Acipimox sodium stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity[1][2][3].
Invitro Acipimox sodium (0-100 µM; 0-4 hours) enhances leptin release from adipocytes isolated from Sprague-Dawley rats in a time- and dose- dependent manner[2].Acipimox sodium (10 mM) stimulats leptin release in adipocytes from Streptozotocin (STZ)-treated and Zucker diabetic fat (ZDF) rats[2].
In Vivo Acipimox sodium (50 mg/kg; i.p.) significantly lowers circulating free fatty acid (FFA) and glucose in high-fat fed mice[3]. Animal Model:
Name Acipimox sodium
CAS 76958-97-9
Formula C6H5N2NaO3
Molar Mass 176.11
Transport Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

Reference [1]. Vestergaard ET, et, al. Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation. Br J Clin Pharmacol. 2017 Dec;83(12):2671-2677. [2]. Wang-Fisher YL, et, al. Acipimox stimulates leptin production from isolated rat adipocytes. J Endocrinol. 2002 Aug;174(2):267-72. [3]. Ahrén B. Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice. Acta Physiol Scand. 2001 Feb;171(2):161-7.

About Contact

© 2008-2024 PeptideDB SYSTEM All Rights Reserved